StreetInsider.com News Articles

Form S-8 Silence Therapeutics

Thu, 05 Mar 2026 16:06:00 +0000

si-local-file:///var/storage/secattach/20260305/26118856.html

Form S-8 Silence Therapeutics

Thu, 05 Mar 2026 16:06:00 +0000

si-local-file:///var/storage/secattach/20260305/26118856.html

Form S-8 Silence Therapeutics

Thu, 05 Mar 2026 16:06:00 +0000

si-local-file:///var/storage/secattach/20260305/26118856.html

Jefferies Reiterates Buy Rating on Silence Therapeutics (SLN): "looks cheap at $175M+ EV"

Thu, 05 Mar 2026 11:42:00 +0000

Jefferies analyst Andrew Tsai reiterated a Buy rating and $25.00 price target on Silence Therapeutics (NASDAQ: SLN)

The analyst commented, "In Aug 2026, divesiran's (TMPRSS6-targeting siRNA) important Phase II polycythemia vera (PV) data could lead to a +50-100% stock move ($1B+ oppty). For SLN's remaining siRNA pipeline: (1) In mid-26, competitor NVS/ IONS' pelacarsen (Lpa ASO) has Phase III CV outcomes data that could help Phase III-ready zerlasiran (Lpa siRNA) attract a BD partner ($1B+ call option). (2) In Q2:26, new preclinical data on cholesterol management (GPR146) and obesity (INHBE). SLN looks cheap at $175M+ EV despite having a mid-/late-stage pipeline

Form 10-K Silence Therapeutics For: Dec 31

Thu, 05 Mar 2026 07:50:00 +0000

si-local-file:///var/storage/secattach/20260305/26115232.html

Form 10-K Silence Therapeutics For: Dec 31

Thu, 05 Mar 2026 07:50:00 +0000

si-local-file:///var/storage/secattach/20260305/26115232.html

Form 10-K Silence Therapeutics For: Dec 31

Thu, 05 Mar 2026 07:50:00 +0000

si-local-file:///var/storage/secattach/20260305/26115232.html

Form 8-K Silence Therapeutics For: Mar 05

Thu, 05 Mar 2026 07:41:00 +0000

si-local-file:///var/storage/secattach/20260305/26115205.html

Form 8-K Silence Therapeutics For: Mar 05

Thu, 05 Mar 2026 07:41:00 +0000

si-local-file:///var/storage/secattach/20260305/26115205.html

Form 8-K Silence Therapeutics For: Mar 05

Thu, 05 Mar 2026 07:41:00 +0000

si-local-file:///var/storage/secattach/20260305/26115205.html

Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results

Thu, 05 Mar 2026 07:30:00 +0000

Topline results for Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for third quarter of 2026

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN, a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on recent business achievements.

“The past year was focused on clinical execution, demonstrated by the expedited enrollment in the Phase 2 SANRECO trial of divesiran in PV which is on-track for topline results in third quarter of 2026,” said

Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results

Thu, 05 Mar 2026 07:30:00 +0000

Topline results for Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for third quarter of 2026

Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results

Thu, 05 Mar 2026 07:30:00 +0000

Topline results for Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for third quarter of 2026

Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results

Thu, 05 Mar 2026 07:30:00 +0000

Topline results for Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for third quarter of 2026

William Blair Reiterates Outperform Rating on Silence Therapeutics (SLN)

Mon, 02 Mar 2026 15:06:20 +0000

William Blair analyst Myles Minter reiterated an Outperform rating on Silence Therapeutics (NASDAQ: SLN)

The analyst commented, "We continue to view divesiran, a GalNAc-conjugated siRNA targeting TMPRSS6 for hepcidin upregulation, as underappreciated. The fully enrolled Phase II placebo-controlled SANRECO trial of divesiran is on track to report top-line data in the third quarter of 2026 with a presentation at ASH in December likely. With rusfertide’s positive Phase III VERIFY study we continue to believe that therapeutic approaches to boost hepcidin levels in PV are de-risked (see: Protagonist's Rusfertide Hits on Phase III Data; Positive Read-Through for Tmprss6-Targeting Asset Class). We continue

Form 4 Silence Therapeutics For: Aug 03 Filed by: Griffiths Richard Ian

Fri, 13 Feb 2026 06:06:00 +0000

si-local-file:///var/storage/secattach/20260213/25995002.html

Form 4 Silence Therapeutics For: Aug 03 Filed by: Griffiths Richard Ian

Fri, 13 Feb 2026 06:06:00 +0000

si-local-file:///var/storage/secattach/20260213/25995002.html

Form 4 Silence Therapeutics For: Aug 03 Filed by: Griffiths Richard Ian

Fri, 13 Feb 2026 06:06:00 +0000

si-local-file:///var/storage/secattach/20260213/25995002.html

Form SCHEDULE 13G/A Silence Therapeutics Filed by: Lombard Odier Asset Management (USA) Corp

Mon, 09 Feb 2026 13:17:00 +0000

si-local-file:///var/storage/secattach/20260209/25967142.html

Form SCHEDULE 13G/A Silence Therapeutics Filed by: Lombard Odier Asset Management (USA) Corp

Mon, 09 Feb 2026 13:17:00 +0000

si-local-file:///var/storage/secattach/20260209/25967142.html

Form SCHEDULE 13G/A Silence Therapeutics Filed by: Lombard Odier Asset Management (USA) Corp

Mon, 09 Feb 2026 13:17:00 +0000

si-local-file:///var/storage/secattach/20260209/25967142.html

Form 8-K Southland Holdings, Inc. For: Feb 04

Wed, 04 Feb 2026 17:30:00 +0000

si-local-file:///var/storage/secattach/20260204/25948390.html

Form 8-K Southland Holdings, Inc. For: Feb 04

Wed, 04 Feb 2026 17:30:00 +0000

si-local-file:///var/storage/secattach/20260204/25948390.html

Form 8-K Southland Holdings, Inc. For: Feb 04

Wed, 04 Feb 2026 17:30:00 +0000

si-local-file:///var/storage/secattach/20260204/25948390.html